iRhythm Builds Momentum Following Large Trial Of AI Approach To ECG Analysis
Executive Summary
Results from a study of more than 91,000 ECG records collected with iRhythm’s Zio ambulatory continuous cardiac monitoring device that demonstrates the successful application of artificial intelligence to ECGs gives the 12-year-old company confidence that it will be profitable very soon.
You may also be interested in...
Reimbursement For Long-Term Cardiac Monitoring Remains Uncertain, iRhythm Reports
Local Medicare carrier Novitas met with monitoring companies to discuss rates for long-term ECG monitoring, but no final decision on recently proposed rate cuts has been reached, iRhythm reported.
UK’s NICE Backs Interim Funding For 14-Day Ambulatory Heart Monitoring Tech
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
IPOs Are Back: Liquid Biopsy, Cardio, Dialysis Firms Lead $1.5Bn Charge
Who wants to go public during a once-in-a-century crisis? It seems like quite a few medtechs do.